Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Intellipharmaceutics (IPCI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 59,564
  • Shares Outstanding, K 30,390
  • Annual Sales, $ 2,250 K
  • Annual Income, $ -10,140 K
  • 36-Month Beta 0.94
  • Price/Sales 28.13
  • Price/Cash Flow 0.00
  • Price/Book 55.01

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.81 +4.76%
on 04/10/17
2.62 -27.63%
on 03/29/17
-0.41 (-17.91%)
since 03/24/17
3-Month
1.81 +4.76%
on 04/10/17
3.12 -39.22%
on 02/03/17
-0.65 (-25.64%)
since 01/24/17
52-Week
1.41 +34.48%
on 06/14/16
3.35 -43.40%
on 11/25/16
-0.18 (-8.84%)
since 04/22/16

Most Recent Stories

More News
IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected

IntelliPharmaCeutics International Inc. (IPCI) reported loss of 7 cents per share in the first quarter of 2017, narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year-ago loss...

AZN : 30.28 (+1.75%)
ENDP : 10.91 (+6.03%)
NVS : 74.62 (+1.66%)
IPCI : 1.89 (-3.57%)
Intellipharmaceutics Announces First Quarter 2017 Results

Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:IPCI) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

IPCI.TO : 2.55 (-4.49%)
IPCI : 1.89 (-3.57%)
Intellipharmaceutics Announces TSX Trading Symbol Change to "IPCI"

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

I.TO : 3.23 (+1.25%)
IPCI : 1.89 (-3.57%)
Biotech's Rise Shows No Sign of Slowing Down in 2017: Today's Reports on IntelliPharmaCeutics and Orexigen Therapeutics

NEW YORK, NY / ACCESSWIRE / February 27, 2017 / The Biotech Industry has posted some impressive gains since Election Day and the rally has continued for the larger part of this year. Both the iShares...

OREX : 3.01 (+4.15%)
XBI : 69.30 (+1.94%)
IPCI : 1.89 (-3.57%)
Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage(R) XR

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

I.TO : 3.23 (+1.25%)
BMY : 53.63 (+0.28%)
IPCI : 1.89 (-3.57%)
Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista(TM) (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pain

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

I.TO : 3.23 (+1.25%)
IPCI : 1.89 (-3.57%)
Research Reports Initiated on Healthcare Stocks Immunovaccine, IntelliPharmaCeutics International, Cardiome Pharma, and Aeterna Zentaris

LONDON, UK / ACCESSWIRE / January 12, 2017 / Active Wall St. announces the list of stocks for today's research reports. Pre-market the Active Wall St. team provides the technical coverage impacting selected...

IMV.TO : 1.22 (+3.39%)
I.TO : 3.23 (+1.25%)
AEZ.TO : 4.02 (+0.50%)
COM.TO : 4.26 (unch)
IPCI : 1.89 (-3.57%)
Research Reports Coverage on Healthcare Stocks -- Pacira Pharma, Supernus Pharma, Lipocine, and IntelliPharmaCeutics

Stock-Callers.com today takes a closer look at the current performances of Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Supernus Pharmaceuticals Inc. (NASDAQ: SUPN), Lipocine Inc. (NASDAQ: LPCN), and IntelliPharmaCeutics...

SUPN : 32.35 (+0.62%)
PCRX : 46.20 (+2.21%)
LPCN : 3.80 (+2.70%)
IPCI : 1.89 (-3.57%)
Intellipharmaceutics Reports on Launch of Additional Strengths of Generic Focalin XR(R) by Par Pharmaceutical

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

I.TO : 3.23 (+1.25%)
IPCI : 1.89 (-3.57%)
Intellipharmaceutics to Present at the Biotech Showcase(TM)

Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and...

I.TO : 3.23 (+1.25%)
IPCI : 1.89 (-3.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Intellipharmaceutics International Inc. is engaged in the research, development, and commercialization of controlled-release and targeted pharmaceutical products. Its products include Effexor XR and Protonix. The Company offers products in different stages of development in therapeutic areas, including...

See More

Support & Resistance

2nd Resistance Point 2.18
1st Resistance Point 2.07
Last Price 1.89
1st Support Level 1.89
2nd Support Level 1.82

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.